AUAUniversity

Advancing Women in Urology: Coaching and Self-Advocacy

Host: Jay D. Raman, MD, FACS

Guest: Dr. Nancy Spector

At the conclusion of this activity, participants will be able to:

1. Describe the importance of working with a coach for career advancement and personal growth.

2. List strategies to obtain coaching.

3. Define key attributes of a healthy and effective coaching relationship.

ACKNOWLEDGEMENT

This educational series was made possible by support from Urovant

Resources:

Institute of Coaching

McLean, Affiliate of Harvard Medical School

https://instituteofcoaching.org/coaching-overview/coaching-benefits#:~:text=The%20benefits%20of%20coaching%20are,(source%3A%20ICF%202009

International Coaching Federation

https://coachingfederation.org/blog/what-makes-a-great-coach

Forbes

https://www.forbes.com/sites/forbescoachescouncil/2018/04/24/your-no-fail-guide-to-selecting-an-executive-coach/?sh=85c2cd611e5c

Advancing Women in Urology: Negotiating for Success (2022)

Advancing Women in Urology, an exciting new educational initiative, has been designed to elevate awareness and provide content that focuses on career tips, advancement, and education featuring women leaders in all areas of urology. The topic for this live course was based on feedback from an AUA survey and a women-led Steering Committee. Dr. Nancy Spector, Executive Director of Executive Leadership in Academic Medicine (ELAM), will moderate an engaging multi-disciplinary panel of three subject matter experts in an interview-style presentation and discussion. This 1-hour, conversation-style webinar will focus on the topic of Negotiation and includes what to consider when negotiating, negotiation strategies, and the impact of not negotiating.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Develop a framework for understanding the importance effective negotiation and self-advocacy has on the advancement of women.

2. Identify negotiation strategies that can be applied to negotiations.

3. Describe the impact negotiation has on the individual, the institution, and to the field.

ACKNOWLEDGEMENT

This educational series was made possible by support from Urovant

Advanced Kidney Cancer: A Guide to Targeted Agents and Immunotherapies

CME Available: https://auau.auanet.org/node/37329

Host: Jay D. Raman, MD, FACS

Co-Hosts: Monika Joshi, MD, MBBS and Brian Matthew Shuch, MD

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to

1. Discuss the current targeted and immunotherapy options available for the treatment of RCC.

2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.

3. Describe best practices in RCC patient selection for treatment options.

4. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme

Advancing Women in Urology: The Importance of Meaningful Mentorship

Host: Jay D. Raman, MD, FACS

Guests: Anne M. Suskind, MD, MS, FACS, FPMRS and Stacy T. Tanaka, MD, MS

Outline:

1. What are the characteristics of a successful mentor or mentee

2. Importance of mentorship for career advancement and personal growth

3. Key characteristics of a healthy/effective relationship

4. Strategies to build effective relationships

5. Why women physicians have difficulty accessing mentors

6. Addressing barriers to acting as a mentor

ACKNOWLEDGEMENT

This educational series was made possible by support from Urovant

Urothelial Carcinoma: Advances in Immuno-Oncology

Host: Jay D. Raman, MD, FACS

Co-Hosts: Andrea Apolo, MD and Sima Porten, MD

CME Available: auau.auanet.org/node/37325

At the conclusion of this activity, participants will be able to

1. Determine the pros/cons of sequencing strategies with chemotherapy and immunotherapy in first line metastatic urothelial carcinoma.

2. Prioritize treatment options in first line metastatic urothelial carcinoma.

3. Evaluate second line options for metastatic urothelial carcinoma.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme

Appropriate use of Biomarker and Genetic Testing in the Diagnosis and Management of Patients with Prostate Cancer

Host: Jay D. Raman, MD, FACS

Co-Hosts: Veda Giri, MD and Todd Morgan, MD

CME Available: auau.auanet.org/node/37313

At the conclusion of this activity, participants will be able to

1. Assess how to maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically meaningful prostate cancer while avoiding unnecessary biopsies and detection of clinically unimportant cancers.

2. Discuss the available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use and the clinical scenarios in which they are most valuable to be used.

3. Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

4. Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy and immunotherapy.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme

Novel Imaging for Genitourinary Cancers

Host: Jay D. Raman, MD, FACS

Co-Host: Marc Bjurlin, DO

CME Available: https://auau.auanet.org/node/37333

At the conclusion of this activity, participants will be able to

1. Review clinical trials and available PET imaging agents for the detection of prostate, kidney and urothelial cancer.

2. Assess the indications, risks, and benefits of incorporating PET imaging to guide treatment of urologic cancer.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme

Systemic Therapies for Metastatic Hormone Sensitive Prostate Cancer and Castrate Resistant Prostate Cancer

Host: Jay D. Raman, MD, FACS

Co-Host: Alicia Morgans, MD, MPH and Kelly Stratton, MD

CME Available: auau.auanet.org/node/37317

At the conclusion of this activity, participants will be able to:

1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.

2. Prioritize or stratify treatment options for metastatic prostate cancer.

3. Describe the mechanism of action and role of immune checkpoint inhibitors for advanced prostate cancer.

4. Identify management of side effects and adverse events that patients experience for systemic therapies for advanced prostate cancer.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme

Today’s episode is a special preview from the 2022 Update Series. The Update Series, the AUA’s most popular self-study CME product is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. Available in three convenient formats – online, print and audio – the Update Series delivers you 40 concise, practical lessons on timely topics including state-of-the-art surgical techniques.

For more episodes like this one or to subscribe to the 2023 Update Series Volume 42, visit the AUAUniversity at auanet.org/update.

Application of the Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline in Clinical Practice

Host: Jay D. Raman, MD, FACS

Co-Host: Michael S. Cookson, MD, MMHC

CME Available: https://auau.auanet.org/node/37309

At the conclusion of this activity, participants will be able to:

1. Interpret the evidence and outcomes on the treatment of M0 HSPC, M1 HSPC, MO CRPC and M1 CRPC as outlined in the newly updated AUA Advanced Prostate Cancer Guideline encompassing metastatic HSPC and CRPC disease.

2. Improve diagnostic and therapeutic decision-making processes by illustrating the application of these guidelines in urological practice.

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from:

Astellas

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lantheus Medical Imaging

Merck & Co., Inc.

Pfizer, Inc.

Sanofi Genzyme